Orion Eyes US Market For Phase III ALS Therapy

Oral Levosimendan May Improve Respiratory Symptoms

07 Feb 2020

• By John Davis

Sales grew but operating profits remained flat in 2019 at Orion Group, as the European mid-sized pharma pursued R&D in amyotrophic lateral sclerosis and cancer.

Espoo, Finland, Where Orion Is Headquartered • Source: Shutterstock

Finland-headquartered Orion Corp.. could market itself an oral formulation of the calcium sensitizer, levosimendan, in the US for amyotrophic lateral sclerosis (ALS), says company chairman and CEO Timo Lappalainen.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

02 May 2025

• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

02 May 2025

• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

01 May 2025

• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

01 May 2025

• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.